[go: up one dir, main page]

PT2419108T - Método para contracepção quando necessária - Google Patents

Método para contracepção quando necessária

Info

Publication number
PT2419108T
PT2419108T PT107170847T PT10717084T PT2419108T PT 2419108 T PT2419108 T PT 2419108T PT 107170847 T PT107170847 T PT 107170847T PT 10717084 T PT10717084 T PT 10717084T PT 2419108 T PT2419108 T PT 2419108T
Authority
PT
Portugal
Prior art keywords
demand contraception
contraception
demand
Prior art date
Application number
PT107170847T
Other languages
English (en)
Inventor
Gainer Erin
Ulmann André
Blithe Diana
Nieman Lynette
Camille Mathe Henri
Original Assignee
Hra Pharma Lab
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42309669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2419108(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hra Pharma Lab, Us Health filed Critical Hra Pharma Lab
Publication of PT2419108T publication Critical patent/PT2419108T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Medicinal Preparation (AREA)
PT107170847T 2009-04-14 2010-04-13 Método para contracepção quando necessária PT2419108T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16914909P 2009-04-14 2009-04-14

Publications (1)

Publication Number Publication Date
PT2419108T true PT2419108T (pt) 2016-11-07

Family

ID=42309669

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107170847T PT2419108T (pt) 2009-04-14 2010-04-13 Método para contracepção quando necessária

Country Status (25)

Country Link
US (4) US9616073B2 (pt)
EP (2) EP2419108B1 (pt)
JP (2) JP5951480B2 (pt)
CN (1) CN102395373A (pt)
AU (1) AU2010237120B8 (pt)
BR (1) BRPI1014035A2 (pt)
CA (1) CA2757496A1 (pt)
CY (1) CY1118236T1 (pt)
DK (1) DK2419108T3 (pt)
ES (1) ES2602134T3 (pt)
HK (1) HK1232150A1 (pt)
HR (1) HRP20161437T1 (pt)
HU (1) HUE029434T2 (pt)
IL (1) IL215524A0 (pt)
LT (1) LT2419108T (pt)
ME (1) ME02548B (pt)
NZ (2) NZ595790A (pt)
PL (1) PL2419108T3 (pt)
PT (1) PT2419108T (pt)
RS (1) RS55331B1 (pt)
RU (1) RU2542779C2 (pt)
SI (1) SI2419108T1 (pt)
SM (1) SMT201600399B (pt)
WO (1) WO2010119029A1 (pt)
ZA (1) ZA201107543B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
PT2419108T (pt) 2009-04-14 2016-11-07 Hra Pharma Lab Método para contracepção quando necessária
DE202011110355U1 (de) * 2011-03-09 2014-01-15 Arstat, Inc. Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes
CN102727457B (zh) * 2011-04-08 2014-05-28 华润紫竹药业有限公司 稳定的醋酸优力司特制剂
FR2987271B1 (fr) 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
US9643994B2 (en) 2012-09-28 2017-05-09 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
ES2672509T3 (es) 2012-09-28 2018-06-14 Aska Pharmaceutical Co., Ltd. Forma polimórfica cristalina de acetato de ulipristal
JP6200493B2 (ja) 2012-09-28 2017-09-20 あすか製薬株式会社 無定形ウリプリスタール酢酸エステル
FR2997627B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2997628B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
JP6254605B2 (ja) 2012-11-22 2017-12-27 バイエル・ファルマ・アクティエンゲゼルシャフト 「オンデマンド」避妊のためのレボノルゲストレルおよびｃｏｘ阻害剤を含む医薬組成物の使用および投与計画
FR2999081B1 (fr) 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
US9655887B2 (en) 2013-05-23 2017-05-23 Bayer Pharma Aktiengesellschaft Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
WO2019204163A1 (en) 2018-04-20 2019-10-24 Tessenderlo Kerley, Inc. Liquid nitrogen fertilizer compositions and additives therefore
EP3575278A1 (en) 2018-05-31 2019-12-04 Tessenderlo Kerley, Inc. Liquid nitrogen fertilizer compositions and additives therefor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
DE1922005A1 (de) 1969-04-24 1970-11-05 Schering Ag Mittel und Methode zur Kontrazeption
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
IL115738A (en) 1994-10-24 2002-05-23 Schering Ag Competitive progesterone antagonists for regulating female fertility as required
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
AU4957999A (en) 1998-07-17 2000-02-07 Pharmacia & Upjohn Company Subcutaneous medroxyprogesterone acetate for contraception
WO2000009136A1 (en) * 1998-08-11 2000-02-24 Akzo Nobel N.V. Progestogen-only contraceptive kit providing good cycle control
YU13902A (sh) * 1999-08-31 2006-01-16 Schering Ag. Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene
EP2033965A3 (en) * 2000-03-17 2012-09-19 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
ES2212912B1 (es) * 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
CA2516319C (en) 2003-02-28 2012-09-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
CN1980660A (zh) * 2004-07-07 2007-06-13 惠氏公司 孕酮受体拮抗剂的避孕方案和试剂盒
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
DE602005026290D1 (de) 2004-07-09 2011-03-24 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
WO2007038796A1 (en) * 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
BRPI0719486A2 (pt) 2006-12-20 2014-02-18 Duramed Pharmaceuticals Inc "forma farmacêutica sólida oral desitegrante, não-efervescente, métodos para tratar uma mulher que necessite de um contraceptivo de emergência, pacote terapêutico para tratar uma mulher que necessite de contracepção de emergência e processo para a preparação de uma forma sólida de dosagem farmacêutica oral desintegrante, não-efervescente"
EA200970646A1 (ru) 2006-12-28 2009-12-30 Репрос Терапьютикс Инк. Способы и составы для улучшения биодоступности антипрогестинов
US7981927B2 (en) * 2007-03-07 2011-07-19 Janssen Pharmaceutica N.V. Steroids derivatives as selective progesterone receptor modulators
CL2008000999A1 (es) * 2007-04-05 2008-10-10 Bayer Schering Pharma Ag Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
EP2234491A4 (en) 2007-12-20 2010-12-22 Teva Womens Health Inc DOSAGE SCHEMES AND PHARMACEUTICAL COMPOSITIONS AND PACKAGING FOR EMERGENCY CONTRACEPTION
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
WO2010066883A1 (en) 2008-12-12 2010-06-17 Laboratoire Hra-Pharma A method for contraception
PT2419108T (pt) 2009-04-14 2016-11-07 Hra Pharma Lab Método para contracepção quando necessária

Also Published As

Publication number Publication date
US10772897B2 (en) 2020-09-15
RU2542779C2 (ru) 2015-02-27
PL2419108T3 (pl) 2017-08-31
SI2419108T1 (sl) 2017-02-28
HK1232150A1 (en) 2018-01-05
US9616073B2 (en) 2017-04-11
CA2757496A1 (en) 2010-10-21
IL215524A0 (en) 2011-12-29
US10159681B2 (en) 2018-12-25
JP2016188232A (ja) 2016-11-04
EP3106167A1 (en) 2016-12-21
US20190209583A1 (en) 2019-07-11
AU2010237120A1 (en) 2011-11-03
NZ615430A (en) 2014-06-27
ME02548B (me) 2017-02-20
WO2010119029A1 (en) 2010-10-21
US20160317555A1 (en) 2016-11-03
RU2011146058A (ru) 2013-05-20
AU2010237120B8 (en) 2015-11-26
CN102395373A (zh) 2012-03-28
RS55331B1 (sr) 2017-03-31
HRP20161437T1 (hr) 2017-02-10
HUE029434T2 (en) 2017-02-28
JP5951480B2 (ja) 2016-07-13
LT2419108T (lt) 2016-12-27
JP2012523446A (ja) 2012-10-04
ZA201107543B (en) 2012-06-27
BRPI1014035A2 (pt) 2016-04-12
US9283233B2 (en) 2016-03-15
ES2602134T3 (es) 2017-02-17
AU2010237120B2 (en) 2015-10-22
EP2419108B1 (en) 2016-08-17
SMT201600399B (it) 2017-01-10
EP2419108A1 (en) 2012-02-22
US20120122828A1 (en) 2012-05-17
US20150174140A1 (en) 2015-06-25
DK2419108T3 (en) 2016-12-05
NZ595790A (en) 2013-11-29
CY1118236T1 (el) 2017-06-28

Similar Documents

Publication Publication Date Title
ZA202006532B (en) Method for decreasing immunogenicity
IL215524A0 (en) Method for on-demand contraception
GB0905140D0 (en) Method
GB0911905D0 (en) Method
GB0902476D0 (en) Method
GB0910707D0 (en) Method
GB0913525D0 (en) Method
GB0913433D0 (en) Method
GB0901444D0 (en) Method
PL2440510T3 (pl) Sposób wytwarzania pentafluoropropanu
GB0916570D0 (en) Method
GB0903316D0 (en) Method
IL214287A0 (en) Method for producing 2-aminobiphenylene
GB0905367D0 (en) Method
GB0916013D0 (en) Method
GB0908770D0 (en) Method
PL2446196T3 (pl) Sposób dostarczania ciepła
GB0902034D0 (en) Method
PL2488673T3 (pl) Sposób
GB0911362D0 (en) Method
GB0904946D0 (en) Method
GB0900560D0 (en) Method
EP2420492A4 (en) PROCESS FOR PREPARING 2-HALOGEN-6-SUBSTITUTED 4-TRIFLUOROMETHYLPYRIDINE
GB0914702D0 (en) Method
GB0908816D0 (en) Method